



Our STN: BL 125643/645

**SUPPLEMENT APPROVAL
REMS MAJOR MODIFICATION**
June 12, 2024

Kite Pharma, Inc.
Attention: Alissa Lee, PharmD
2400 Broadway
Santa Monica, CA 90404

Dear Dr Lee:

We have approved your request received March 25, 2024, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for axicabtagene ciloleucel (YESCARTA) and to include a major modification to the approved Risk Evaluation and Mitigation Strategy (REMS).

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) was originally approved on July 24, 2020, and the most recent REMS modification was approved on December 15, 2023. The REMS consists of elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

In accordance with section 505-1(g)(4)(B) of the Federal Food, Drug, and Cosmetic Act (FDCA), we have determined that your approved REMS for YESCARTA and TECARTUS must be modified to minimize the burden on the healthcare delivery system of complying with the REMS. Your approved REMS must be modified as follows:

- Modification to REMS goals: The goal for “Ensuring those who prescribe, dispense, or administer YESCARTA and/or TECARTUS are aware of how to manage the risks of CRS and neurological toxicities” is no longer necessary to ensure the benefits of the drugs outweigh the risks and must be removed.
- Removal of requirement for educational and training materials: Patient Wallet Card, Program Training, Knowledge Assessment, and Adverse Reaction Management Guide.
- Removal of requirement to report any serious adverse events suggestive of CRS or neurological toxicities to the REMS.

Your proposed modified REMS, submitted on June 7, 2024, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS remains the same as that approved on July 24, 2020. The REMS assessment plan has been revised to remove education statistics to align with the above REMS modification. The REMS assessment plan must include, but is not limited to, the following:

For the annual assessments:

The REMS Program Infrastructure and Performance (provide in tabular format as appropriate)

- A. Hospitals and their associated clinics enrollment statistics
 - List of all enrolled hospital sites, locations, dates of enrollment, and method (email, fax) of enrollment and dates of certification notification;
 - Number of incomplete enrollments at the time of assessment data lock.
- B. Utilization of YESCARTA or TECARTUS
 - Number and age of patients treated with YESCARTA or TECARTUS; provide number treated at each certified hospital;
 - Number and age of patients for which YESCARTA or TECARTUS was ordered but never infused and the reason(s) that the patient was not treated; provide number of occurrences at each certified hospital for each reporting period and cumulatively;
 - Time between certification and first order for YESCARTA or TECARTUS for each hospital certified during the assessment period.
- C. Compliance with YESCARTA and TECARTUS REMS
 - Number and name of non-certified hospital(s) that have treated a patient with YESCARTA or TECARTUS and any corrective actions taken to prevent future occurrences and the number of these that subsequently became certified;
 - Audits: A summary of findings from first-order audits and annual audits and any action taken and outcome of actions to prevent future occurrences;
 - Summary of findings for monitoring conducted during the reporting period by hospitals, including any corrective and preventative actions (CAPA).
- D. YESCARTA and TECARTUS REMS Customer Care Center
 - Number of contacts by stakeholder type (patient/guardian, prescriber, hospital and their associated clinic authorized representative, other health care provider (HCP), other);
 - Summary of frequently asked questions (FAQ) by stakeholder type;
 - Summary of any non-compliance that is identified through call center contacts, source of report and resulting corrective and preventative actions.

- E. With respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether one or more such goals or such elements should be modified (Section 505-1(g)(3)).

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication;
- b) A determination of the implications of a change in the benefit-risk profile for the current REMS;
- c) *If the new indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of the last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS.
- g) *If you are not proposing REMS modifications,* provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively,

updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

BLA 125643 REMS CORRESPONDENCE

(insert concise description of content in bold capital letters, e.g., UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY)

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

BLA 125643 REMS ASSESSMENT

or

**NEW SUPPLEMENT FOR BLA 125643
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA 125643
PRIOR APPROVAL SUPPLEMENT
PROPOSED MAJOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA 125643
PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABEL CHANGES
SUBMITTED IN SUPPLEMENT XXX**

or

**NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR BLA 125643
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

REMS REVISIONS FOR BLA 125643

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT

As soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in Structured Product Labeling (SPL) format using the FDA automated drug registration and listing system (eLIST). Content of the REMS document must be identical to the approved REMS document. The SPL will be publicly available.

Information on submitting REMS in SPL format may be found in the guidance for industry *Providing Regulatory Submission in Electronic Format – Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling*.

For additional information on submitting REMS in SPL format, please email FDAREMSwebsite@fda.hhs.gov.

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

We will include information contained in the above-referenced supplements in your BLA files.

Sincerely,

Lola Fashoyin-Aje, MD, MPH
Acting Director
Division of Clinical Evaluation Hematology
Office of Clinical Evaluation
Office of Therapeutic Products
Center for Biologics Evaluation and Research

Enclosures:
REMS